S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

Humanigen Stock Price, News & Analysis (OTCMKTS:HGEN)

$0.70
-0.02 (-2.78 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$0.70
Now: $0.70
$0.72
50-Day Range
$0.60
MA: $0.81
$0.99
52-Week Range
$0.46
Now: $0.70
$1.54
Volume1,100 shs
Average Volume6,964 shs
Market Capitalization$78.95 million
P/E RatioN/A
Dividend YieldN/A
Beta3.07
Humanigen, Inc., a biopharmaceutical company, engages in developing its proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's products include lenzilumab and ifabotuzumab, which are monoclonal antibodies derived from Humaneered platform. Lenzilumab targets granulocyte-macrophage colony-stimulating factor (GM-CSF), and is in development as a potential medicine for chimeric antigen receptor T cell (CAR-T) therapy, as well as a potential treatment for rare hematologic cancers, such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab targets Ephrin type-A receptor 3 (EphA3), and is being explored as a potential treatment for glioblastoma multiforme (GBM) and other cancers, as well as for use in novel CAR-T construct and bispecific antibody platform. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HGEN
Previous SymbolNASDAQ:KBIO
CUSIPN/A
Phone650-243-3100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.07) per share

Profitability

Net Income$-12,000,000.00

Miscellaneous

Employees3
Market Cap$78.95 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive HGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for HGEN and its competitors with MarketBeat's FREE daily newsletter.


Humanigen (OTCMKTS:HGEN) Frequently Asked Questions

What is Humanigen's stock symbol?

Humanigen trades on the OTCMKTS under the ticker symbol "HGEN."

How were Humanigen's earnings last quarter?

Humanigen Inc (OTCMKTS:HGEN) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.03) earnings per share for the quarter. View Humanigen's Earnings History.

When is Humanigen's next earnings date?

Humanigen is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Humanigen.

Has Humanigen been receiving favorable news coverage?

Media coverage about HGEN stock has trended negative on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Humanigen earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Humanigen.

Who are some of Humanigen's key competitors?

What other stocks do shareholders of Humanigen own?

Who are Humanigen's key executives?

Humanigen's management team includes the folowing people:
  • Dr. Cameron Durrant M.B.A., M.D., MBA, Chairman & CEO (Age 59)
  • Mr. J. Gregory Jester, Chief Financial Officer (Age 51)
  • Mr. Christopher Bowe, Head of Corp. Affairs
  • Dr. Tarek Sahmoud, Chief Medical Officer

How do I buy shares of Humanigen?

Shares of HGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Humanigen's stock price today?

One share of HGEN stock can currently be purchased for approximately $0.70.

How big of a company is Humanigen?

Humanigen has a market capitalization of $78.95 million. Humanigen employs 3 workers across the globe.View Additional Information About Humanigen.

What is Humanigen's official website?

The official website for Humanigen is http://www.humanigen.com/.

How can I contact Humanigen?

Humanigen's mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The company can be reached via phone at 650-243-3100 or via email at [email protected]


MarketBeat Community Rating for Humanigen (OTCMKTS HGEN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  80 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about Humanigen and other stocks. Vote "Outperform" if you believe HGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Featured Article: What is the Current Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel